HIV Citation List: September 16, 2011 - September 29, 2011

Pubmed citations

1. P1-Substituted Symmetry-Based Human Immunodeficiency Virus Protease Inhibitors with Potent Antiviral Activity against Drug-Resistant Viruses. Degoey, D.A., D.J. Grampovnik, H.J. Chen, W.J. Flosi, L.L. Klein, T. Dekhtyar, V. Stoll, M. Mamo, A. Molla, and D.J. Kempf, Journal of Medicinal Chemistry, 2011. [Epub ahead of print]; PMID[21899332].
[PubMed]. HIV_0916-092911.

2. Mechanism of HIV reverse transcriptase inhibition by zinc: formation of a highly stable enzyme-(primer-template) complex with profoundly diminished catalytic activity. Fenstermacher, K.J. and J.J. Destefano, Journal of Biological Chemistry, 2011. [Epub ahead of print]; PMID[21953456].
[PubMed]. HIV_0916-092911.

3. Design, Synthesis, and X-ray Crystallographic Analysis of a Novel Class of HIV-1 Protease Inhibitors. Ganguly, A.K., S.S. Alluri, D. Caroccia, D. Biswas, C.H. Wang, E. Kang, Y. Zhang, A.T. McPhail, S.S. Carroll, C. Burlein, V. Munshi, P. Orth, and C. Strickland, Journal of Medicinal Chemistry, 2011. [Epub ahead of print]; PMID[21916489].
[PubMed]. HIV_0916-092911.

4. Use of silver nanoparticles increased inhibition of cell-associated HIV-1 infection by neutralizing antibodies developed against HIV-1 envelope proteins. Lara, H.H., L. Ixtepan-Turrent, E.N. Garza Trevino, and D.K. Singh, Journal of Nanobiotechnology, 2011. 9(1): p. 38; PMID[21923937].
[PubMed]. HIV_0916-092911.

5. Structural and biochemical characterization of the inhibitor complexes of XMRV protease. Li, M., A. Gustchina, K. Matuz, J. Tozser, S. Namwong, N.E. Goldfarb, B.M. Dunn, and A. Wlodawer, The FEBS Journal, 2011. [Epub ahead of print]; PMID[21951660].
[PubMed]. HIV_0916-092911.

6. Activity and Safety of Synthetic Lectins Based on Benzoboroxole-Functionalized Polymers for Inhibition of HIV Entry. Mahalingam, A., A.R. Geonnotti, J. Balzarini, and P.F. Kiser, Molecular Pharmaceutics, 2011. [Epub ahead of print]; PMID[21879735].
[PubMed]. HIV_0916-092911.

7. Docking, molecular dynamics and quantitative structure-activity relationship studies for HEPTs and DABOs as HIV-1 reverse transcriptase inhibitors. Mao, Y., Y. Li, M. Hao, S. Zhang, and C. Ai, Journal of Molecular Modeling, 2011. [Epub ahead of print]; PMID[21947448].
[PubMed]. HIV_0916-092911.

8. Anti-HIV-1 and cytotoxicity of the alkaloids of Erythrina abyssinica Lam. growing in Sudan. Mohammed, M.M., N.A. Ibrahim, N.E. Awad, A.A. Matloub, A.G. Mohamed-Ali, E.E. Barakat, A.E. Mohamed, and P.L. Colla, Natural Product Research, 2011. [Epub ahead of print]; PMID[21936641].
[PubMed]. HIV_0916-092911.

9. Measurement of antiviral activity in drugs for HIV-1. Siliciano, R.F., The Lancet Infectious Diseases 2011. [Epub ahead of print]; PMID[21933753].
[PubMed]. HIV_0916-092911.

10. The hematopoietic cell-specific Rho GTPase inhibitor ARHGDIB/D4GDI limits HIV-1 replication. Watanabe, T., E. Urano, K. Miyauchi, R. Ichikawa, M. Hamatake, N. Misawa, K. Sato, H. Ebina, Y. Koyanagi, and J. Komano, AIDS Research and Human Retroviruses, 2011. [Epub ahead of print]; PMID[21936715].
[PubMed]. HIV_0916-092911.

11. Development of indole compounds as small molecule fusion inhibitors targeting HIV-1 glycoprotein-41. Zhou, G., D. Wu, B. Snyder, R.G. Ptak, H. Kaur, and M. Gochin, Journal of Medicinal Chemistry, 2011. [Epub ahead of print]; PMID[21928824].
[PubMed]. HIV_0916-092911.

12. Zinc-finger antiviral protein inhibits HIV-1 infection by selectively targeting multiply spliced viral mRNAs for degradation. Zhu, Y., G. Chen, F. Lv, X. Wang, X. Ji, Y. Xu, J. Sun, L. Wu, Y.T. Zheng, and G. Gao, Proceedings of the National Academy of Sciences of the United States of America, 2011. 108(38): p. 15834-9; PMID[21876179].
[PubMed]. HIV_0916-092911.

ISI Web of Knowledge citations

13. Structure-Activity Relationship Studies of HIV-1 Integrase Oligonucleotide Inhibitors. Agapkina, J., T. Zatsepin, E. Knyazhanskaya, J.F. Mouscadet, and M. Gottikh, Acs Medicinal Chemistry Letters, 2011. 2(7): p. 532-537; PMID[WOS:000294385600010].
[WOS]. HIV_0916-092911.

14. Analogues of a lupane-type triterpene as potential anti-HIV agents. Callies, O., L. Bedoya, A. Munoz, I. Jimenez, J. Alcami, and I. Bazzocchi, Planta Medica, 2011. 77(12): p. 1255-1255; PMID[WOS:000294139000093].
[WOS]. HIV_0916-092911.

15. d(TGGGAG) with 5 '-nucleobase-attached large hydrophobic groups as potent inhibitors for HIV-1 envelop proteins mediated cell-cell fusion. Chen, W., L. Xu, L. Cai, B. Zheng, K. Wang, J. He, and K. Liu, Bioorganic & Medicinal Chemistry Letters. 2011. 21(19): p. 5762-5764; PMID[WOS:000294714400021].
[WOS]. HIV_0916-092911.

16. Crystal structure of HIV-1 reverse transcriptase (RT)/dsDNA/non-nucleoside inhibitor complex for understanding inhibition and drug resistance. Das, K., S.E. Martinez, and E. Arnold, Antiviral Therapy, 2011. 16(4): p. A56-A56; PMID[WOS:000294375700067].
[WOS]. HIV_0916-092911.

17. TMC310911, a novel HIV type-1 protease inhibitor with an improved resistance coverage and a higher genetic barrier compared to currently approved protease inhibitors. Dierynck, I., H. Van Marck, M. Van Ginderen, T. Jonckers, A. Raoof, G. Kraus, and G. Picchio, Antiviral Therapy, 2011. 16(4): p. A11-A11; PMID[WOS:000294375700027].
[WOS]. HIV_0916-092911.

18. Dibenzocyclooctadiene lignans from Schisandra neglecta and their anti-HIV-1 activities. Duan, Y.X., J.L. Cao, R.R. Wen, G.Y. Yang, J.X. Pu, H.D. Sun, W.L. Xiao, and G.P. Li, Journal of Asian Natural Products Research, 2011. 13(7): p. 592-598; PMID[WOS:000294801900003].
[WOS]. HIV_0916-092911.

19. Microwave Assisted Organic Synthesis (MAOS) of Small Molecules as Potential HIV-1 Integrase Inhibitors. Ferro, S., S. De Grazia, L. De Luca, R. Gitto, C.E. Faliti, Z. Debyzer, and A. Chimirri, Molecules, 2011. 16(8): p. 6858-6870; PMID[WOS:000294249100054].
[WOS]. HIV_0916-092911.

20. Tetrahydrofuran, tetrahydropyran, triazoles and related heterocyclic derivatives as HIV protease inhibitors. Ghosh, A.A., DD, Future Medicinal Chemistry, 2011. 3(9): p. 1181-1197; PMID[WOS:000294460400015].
[WOS]. HIV_0916-092911.

21. tert-Butyl N-[3-hydroxy-1-phenyl-4-(pyrimidin-2-ylsulfanyl)butan-2-yl]carbamate monohydrate. Gomes, C.R.B., T.R.A. Vasconcelos, W.T. Vellasco, J.L. Wardell, S. Wardell, and E.R.T. Tiekink, Acta Crystallographica Section E-structure Reports Online, 2011. 67: p. O2313-U2440; PMID[WOS:000294714600201].
[WOS]. HIV_0916-092911.

22. Synthesis and biological evaluation of HQCAs with aryl or benzyl substituents on N-1 position as potential HIV-1 integrase inhibitors. He, Q., X. Zhang, H. Wu, S. Gu, X. Ma, L. Yang, Y. Zheng, and F. Chen, Bioorganic & Medicinal Chemistry, 2011. 19(18): p. 5553-5558; PMID[WOS:000294711100027]. [WOS]. HIV_0916-092911.

23. Anti HIV-1 Agents 7. Discovery of 1-Hydroxy-4-chloro-9,10-anthraquinone Derivatives as New HIV-1 Inhibitors in Vitro. Huang, N., Q. Wang, L. Yang, H. Xu, and Y. Zheng, Letters in Drug Design & Discovery, 2011. 8(7): p. 602-605; PMID[WOS:000294410600004].
[WOS]. HIV_0916-092911.

24. Structure-function studies of HIV-1 protease drug resistance to tipranavir and darunavir. Kovari, L.C., Y. Wang, and J. Brunzelle, Antiviral Therapy, 2011. 16(4): p. A61-A61; PMID[WOS:000294375700072]. [WOS]. HIV_0916-092911.

25. Antiviral Activity of Substituted Salicylanilides - A Review. Kratky, M.V., J, Mini-Reviews in Medicinal Chemistry, 2011. 11(11): p. 956-967; PMID[WOS:000294704600003].
[WOS]. HIV_0916-092911.

26. Anti-AIDS agents 87. New bio-isosteric dicamphanoyl-dihydropyranochromone (DCP) and dicamphanoyl-khellactone (DCK) analogues with potent anti-HIV activity. Liu, H., S. Xu, M. Cheng, Y. Chen, P. Xia, K. Qian, Y. Xia, Z. Yang, C. Chen, S. Morris-Natschke, and K. Lee, Bioorganic & Medicinal Chemistry Letters, 2011. 21(19): p. 5831-5834; PMID[WOS:000294714400037]. [WOS]. HIV_0916-092911.

27. Synthesis and biological evaluation of 2 ',4 '- and 3 ',4 '-bridged nucleoside analogues. Nicolaou, K.C., S.P. Ellery, F. Rivas, K. Saye, E. Rogers, T.J. Workinger, M. Schallenberger, R. Tawatao, A. Montero, A. Hessell, F. Romesberg, D. Carson, and D. Burton, Bioorganic & Medicinal Chemistry, 2011. 19(18): p. 5648-5669; PMID[WOS:000294711100037].
[WOS]. HIV_0916-092911.

28. Anti-HIV activity of Delta 18-oleane triterpenoids from Cassine xylocarpa. Osorio, A.A., D.F. Torres, L.M. Bedoya, A. Munoz, J. Alcami, and I.L. Bazzocchi, Planta Medica, 2011. 77(12): p. 1341-1341; PMID[WOS:000294139000452].
[WOS]. HIV_0916-092911.

29. New betulinic acid derivatives as potent proteasome inhibitors. Qian, K., S. Kim, H. Hung, L. Huang, C. Chen, and K. Lee, Bioorganic & Medicinal Chemistry Letters, 2011. 21(19): p. 5944-5947; PMID[WOS:000294714400061].
[WOS]. HIV_0916-092911.

30. Subunit-specific mutational analysis of residue N348 in HIV-1 reverse transcriptase. Radzio, J. and N. Sluis-Cremer, Retrovirology, 2011. 8; PMID[WOS:000294607900001].
[WOS]. HIV_0916-092911.

31. Classification Structure-Activity Relationship Study of Reverse Transcriptase Inhibitors. Seyagh, M., E.L.M. Mazouz, A. Schmitzer, D. Villemin, A. Jarid, and D. Cherqaoui, Letters in Drug Design & Discovery, 2011. 8(7): p. 585-595; PMID[WOS:000294410600002].
[WOS]. HIV_0916-092911.

32. Synthesis, in vitro evaluation, and docking studies of novel chromone derivatives as HIV-1 protease inhibitor. Ungwitayatorn, J., C. Wiwat, W. Samee, P. Nunthanavanit, and N. Phosrithong, Journal of Molecular Structure, 2011. 1001(1-3): p. 152-161; PMID[WOS:000294393900022].
[WOS]. HIV_0916-092911.

33. Microwave assisted synthesis of 4-thiazolidinones and its 5-arylidene derivatives: Screening of antimicrobial activity with various microorganisms. Upadhyay, A., S.K. Srivastava, S.D. Srivastava, and N. Upadhyay, Journal of the Indian Chemical Society, 2011. 88(7): p. 1025-1031; PMID[WOS:000294506200018].
[WOS]. HIV_0916-092911.

34. Synthesis and Reactions of 1-Amino-5-morpholin-4-yl-6,7,8,9-tetrahydrothieno[2,3-c]isoquinoline. Zaki, R.M., S.M. Radwan, and A.M.K. El-Dean, Journal of the Chinese Chemical Society, 2011. 58(4): p. 544-554; PMID[WOS:000293610200019].
[WOS]. HIV_0916-092911.

35. Quantitative Structure-Activity Relationship of IOPY/ISPY Analogues as HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors. Zhu, R., F. Wang, Q. Liu, and T. Kang, Acta Chimica Sinica, 2011. 69(15): p. 1731-1736; PMID[WOS:000294375200002].
[WOS]. HIV_0916-092911.

Patent citations:

36. Preparation of betulin derivatives for treatment of HIV-1. Gao, D., N. Han, Z. Jin, F. Ning, J. Tang, Y. Wu, and H. Yang, 2011, (GlaxoSmithKline LLC, USA). Application: WO WO. p. 52pp.
[Patent]. HIV_0916-092911.

37. Preparation of styrylquinolines and their therapeutic uses as integrase inhibitors and for the treatment and prevention of HIV. Giethlen, B., M. Michaut, C. Monneret, E. Soma, L. Thibault, and C.G. Wermuth, 2011, (BioAlliance Pharma, Fr.). Application: US US. p. 18pp , Cont -in-part of U S Ser No 269,241. [Patent]. HIV_0916-092911.

38. Ferrocenyl flavonoids. Hillard, E., G. Chabot, J.-P. Monserrat, G. Jaouen, K.N. Tiwari, F. De Montigny, and N. Neamati, 2011, (Centre National de la Recherche Scientifique (CNRS), Fr.). Application: WO WO. p. 50pp.
[Patent]. HIV_0916-092911.

39. Preparation of oxazinonaphthyridine derivatives for use as anti-HIV agents. Jin, H., C.U. Kim, and B.W. Phillips, 2011, (Gilead Sciences, Inc., USA). Application: WO WO. p. 56pp.
[Patent]. HIV_0916-092911.

40. CXCR4 receptor allosteric modulators. 2011, (Anchor Therapeutics, Inc., USA). Looby, R.J. and B. Tchernychev, Application: WO WO. p. 142pp.
[Patent]. HIV_0916-092911.

41. Preparation of 1,3,4,8-tetrahydro-2H-pyrido[1,2-a]pyrazine derivatives and their use as HIV integrase inhibitors. Miyazaki, S., Y. Bessho, K. Adachi, S. Kawashita, H. Isoshima, K. Oshita, and S. Fukuda, 2011, (Japan Tobacco Inc., Japan). Application: WO p 278pp.
[Patent]. HIV_0916-092911.

42. 1-Phenyl-1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione derivatives as HIV replication inhibitors and their preparation and use for the treatment of HIV infection. 2011, (Boehringer Ingelheim International GmbH, Germany). Simoneau, B., P. Deroy, L. Fader, A.-M. Faucher, A. Gagnon, C. Grand-Maitre, S. Kawai, S. Landry, J.-F. Mercier, and J. Rancourt, Application: WO p.122pp.
[Patent]. HIV_0916-092911.